|
Market Closed -
Nasdaq Stockholm
09:30:00 24/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 1.828 SEK | +2.01% |
|
+1.90% | -7.21% |
| 03/09 | Irlab CEO Kristina Torfgaard to step down in 2027 | FW |
| 03/09 | Irlab CEO Kristina Torfgaard wants to step down | FW |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Pharmaceuticals | 21Cr | 6.11Cr | 56.78L | 9.46Cr | 5.75Cr | |||||
Total Assets | 47Cr | 32Cr | 18Cr | 14Cr | 14Cr | |||||
Interest Expense | -4L | -3L | -2L | -1.05Cr | -1.8Cr | |||||
Income Tax Expense | - | - | - | - | - | |||||
CAPEX | -7L | -28.76L | -3L | -2L | - | |||||
EBT | 5.18Cr | -11Cr | -18Cr | -8.31Cr | -11Cr | |||||
D&A | 32.15L | 37.23L | 43.16L | 45.83L | 43.19L | |||||
Operating Income | 5.26Cr | -11Cr | -18Cr | -7.51Cr | -9.34Cr | |||||
Net Income | 5.18Cr | -11Cr | -18Cr | -8.31Cr | -11Cr |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | - | - | 42.2L | 9.46Cr | 5.75Cr | |||||
United Kingdom | 21Cr | 6.11Cr | 14.58L | - | - | |||||
| - | - | - | - | 5.75Cr | ||||||
Sweden | - | - | - | - | - | |||||
Total Assets | 5.1Cr | 5.49Cr | 5.35Cr | 5.67Cr | 5.23Cr | |||||
Interest Expense | - | - | - | - | - | |||||
Income Tax Expense | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Net Income | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - |
- Stock Market
- Stocks
- IRLAB A Stock
- Financials IRLAB Therapeutics AB
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
